US FDA to explain why some approval decisions differ from advisory panel views
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration’s pledge as part of its transparency initiative to explain why it did not follow an advisory panel’s recommendations appears to extend only to those occasions when the agency approves a drug against a committee’s advice, and not when it rejects a new drug application or biologics licence application1,2.